Aldeyra Therapeutics Stock News

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Aldeyra Therapeutics (NASDAQ:ALDX) had its target price lowered by SVB Leerink from $24.00 to $15.00 in a research note published on Tuesday, Analyst Price Targets reports. SVB Leerink currently has an outperform rating on the biotechnology companys stock. SVB Leerink also issued estimates for Aldeyra Therapeutics FY2022 earnings at ($1.00) EPS, FY2023 earnings at ($2.10) []

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Analysts at SVB Leerink lifted their FY2022 EPS estimates for shares of Aldeyra Therapeutics in a report issued on Monday, December 20th. SVB Leerink analyst M. Goodman now anticipates that the biotechnology company will post earnings of ($1.00) per share for the year, up from their previous forecast of ($1.20). []

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Investment analysts at Oppenheimer reduced their FY2021 earnings per share (EPS) estimates for Aldeyra Therapeutics in a report released on Monday, December 20th. Oppenheimer analyst J. Kim now anticipates that the biotechnology company will earn ($1.11) per share for the year, down from their previous forecast of ($1.09). Oppenheimer also []

Aldeyra Therapeutics reported top-line results from their phase three trial, TRANQUILITY, evaluating Reproxalap in the treatment of dry eye disease; the trial missed the primary endpoint of improving

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) with the stream of -50.91% also noticed, India PG&E Corporation (NYSE:PCG) encountered a rapid change of 0.67% in the last hour of Tuesdays trading session. Aldeyra The post May This Data Fuel Up Investors Confidence? Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), PG&E Corporation (NYSE:PCG) appeared first on Stocks Equity .

Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The SP also rose, gaining 0.80% to 4,605.08. The U.S. has the highest number of coronavirus cases

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial failed to meet the primary endpoint of

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocul

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.24 and traded as low as $6.70. Aldeyra Therapeutics shares last traded at $7.01, with a volume of 797,943 shares. ALDX has been the subject of a number of research reports. []

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

In the last trading session, 1.09 million Aldeyra Therapeutics Inc. (NASDAQ:ALDX) shares changed hands as the companys beta touched 1.67. With the companys per share price at $7.33 changed hands at $0.44 or 6.39% during last session, the market valuation stood at $452.99M. ALDXs last price was a discount, traded about -117.6% off its 52-week Aldeyra Therapeutics Inc. (NASDAQ: ALDX): Time To Buy Over The Next Few Months Read More »